Alnylam Pharmaceuticals, Inc. (ALNY) Cash Flow Statement
Alnylam Pharmaceuticals, Inc. (ALNY) generated $911.8M of operating cash flow over the twelve months to 2026-06-30, spent $91.9M on capital expenditure and had free cash flow of $819.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALNYAlnylam Pharmaceuticals, Inc.Follow ALNY — free
—
Price chart with a free account
- Market cap
- 30.0B
- P/E TTM
- 41.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2010 Dec 10 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.08 | -0.56 | -0.28 | -0.61 | -0.64 | -0.54 | 0.10 | -0.01 | 0.52 | 0.91 | |
| Capital expenditure | 0.00 | 0.13 | 0.14 | 0.07 | 0.08 | 0.07 | 0.06 | 0.03 | 0.06 | -0.09 | |
| Free cash flow | -0.09 | -0.69 | -0.42 | -0.69 | -0.72 | -0.61 | 0.04 | -0.04 | 0.47 | 0.82 | |
| Stock-based compensation | 0.02 | 0.16 | 0.17 | 0.14 | 0.17 | 0.23 | 0.22 | 0.27 | 0.35 | — |
USD billions · SEC XBRL
Alnylam Pharmaceuticals, Inc. — questions
- What is Alnylam Pharmaceuticals, Inc.'s operating cash flow?
- $911.8M over the twelve months to 2026-06-30.
- How much does Alnylam Pharmaceuticals, Inc. spend on capital expenditure?
- $91.9M over the twelve months to 2026-06-30.
- What is Alnylam Pharmaceuticals, Inc.'s free cash flow?
- $819.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Alnylam Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.